We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Perspective Therapeutics, Inc. (CATX) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Perspective Therapeutics (CATX - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Perspective Therapeutics is a member of our Medical group, which includes 1019 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Perspective Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for CATX's full-year earnings has moved 0.5% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, CATX has gained about 200.8% so far this year. At the same time, Medical stocks have gained an average of 6.7%. This means that Perspective Therapeutics is performing better than its sector in terms of year-to-date returns.
Adma Biologics (ADMA - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 263.9%.
The consensus estimate for Adma Biologics' current year EPS has increased 16.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Perspective Therapeutics belongs to the Medical - Drugs industry, a group that includes 178 individual stocks and currently sits at #87 in the Zacks Industry Rank. Stocks in this group have lost about 4.2% so far this year, so CATX is performing better this group in terms of year-to-date returns.
On the other hand, Adma Biologics belongs to the Medical - Biomedical and Genetics industry. This 498-stock industry is currently ranked #71. The industry has moved -2.3% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Perspective Therapeutics and Adma Biologics as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Perspective Therapeutics, Inc. (CATX) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Perspective Therapeutics (CATX - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Perspective Therapeutics is a member of our Medical group, which includes 1019 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Perspective Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for CATX's full-year earnings has moved 0.5% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, CATX has gained about 200.8% so far this year. At the same time, Medical stocks have gained an average of 6.7%. This means that Perspective Therapeutics is performing better than its sector in terms of year-to-date returns.
Adma Biologics (ADMA - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 263.9%.
The consensus estimate for Adma Biologics' current year EPS has increased 16.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Perspective Therapeutics belongs to the Medical - Drugs industry, a group that includes 178 individual stocks and currently sits at #87 in the Zacks Industry Rank. Stocks in this group have lost about 4.2% so far this year, so CATX is performing better this group in terms of year-to-date returns.
On the other hand, Adma Biologics belongs to the Medical - Biomedical and Genetics industry. This 498-stock industry is currently ranked #71. The industry has moved -2.3% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Perspective Therapeutics and Adma Biologics as they could maintain their solid performance.